New hope for schizophrenia: drug switch study shows promise
NCT ID NCT05628103
First seen Nov 12, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This study looked at whether people with schizophrenia could safely switch to a new medication called SEP-363856 from their current antipsychotic drugs. About 100 stable patients took the new drug for 8 weeks. Researchers tracked how many stopped treatment due to side effects or lack of benefit, and how many stayed on the drug for any reason.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Discovery Research LLC
Atlanta, Georgia, 30318, United States
-
Advanced Research Center, Inc.
Anaheim, California, 92805, United States
-
Atlanta Behavioral Research
Atlanta, Georgia, 30358, United States
-
Atlanta Center for Medical Research
Atlanta, Georgia, 30331, United States
-
CBH Health
Gaithersburg, Maryland, 20877, United States
-
CMB Clinical Trials
Santee, California, 92071, United States
-
California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC)
San Diego, California, 92102, United States
-
Cenexel CNS Research
Torrance, California, 90502, United States
-
Charak Clinical Research Center
Garfield Heights, Ohio, 44125, United States
-
Clinical Innovations Inc.
Bellflower, California, 90706, United States
-
Clinical Innovations, Inc
Riverside, California, 92506, United States
-
Clinical Trials of America, LLC
Hickory, North Carolina, 28601, United States
-
Collaborative Neuroscience Research, LLC
Garden Grove, California, 92845, United States
-
Hassman Research Institute
Berlin, New Jersey, 08009, United States
-
IMA Clinical Research
Las Vegas, Nevada, 89102, United States
-
Larkin Behavioral Health Services
Hollywood, Florida, 33021, United States
-
New Hope Clinical Research
Charlotte, North Carolina, 28211, United States
-
Nova Psychiatry, Inc.
Orlando, Florida, 32803, United States
-
Pillar Clinical Research, LLC
Richardson, Texas, 75080, United States
-
Premier Clinical Research Institute, Inc.
Miami, Florida, 33122, United States
-
ProScience Research Group
Culver City, California, 90230, United States
-
PsychCare Consultants Research
St Louis, Missouri, 63128, United States
-
Synergy San Diego
Lemon Grove, California, 91945, United States
-
Uptown Research
Chicago, Illinois, 60640, United States
-
Wellness Research Center
Miami, Florida, 33135, United States
Conditions
Explore the condition pages connected to this study.